Summary: The fiscal year 2025 (FY25) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY25 PRMRP topic areas and one of the FY25 PRMRP strategic goals. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision making tools or practice guidelines. Products in development should be responsive to the health care needs of military Service Members, Veterans, and their Families.

Distinctive Features: For the PRMRP TTDA, the program expects the research proposed will take an already established proof-of-concept or prototype through the final stages of preclinical development. The PRMRP also expects that the research outcome will be a regulatory filing or translation of findings into clinical practice, as applicable.

Miscellaneous

• Unrestricted